I'll research STERIS (STE) before writing the preview. Let me gather recent earnings materials, guidance, and news.Let me read the most recent earnings release and call (Q4 FY2026, reported May 2026), which set FY2027 guidance.Now let me pull last year's Q1 (the comp) and recent stock price/news context.Let me check what drove the late-July rally and find consensus estimates.I have what I need. Let me write the preview.
STERIS heads into its fiscal Q1 print riding a strong tape. The stock has rallied roughly 10% in the back half of July — from the low-$210s to ~$233 (closing at $232.89 on Aug 4) — including a sharp ~5% jump on July 28, likely on the back of upbeat med-tech peer results and procedure-volume commentary. That rally raises the bar: expectations have re-rated higher just as STE enters a quarter management itself flagged as a softer start to the year.
Consensus expectations (analyst estimates): - Revenue: ~$1.51 billion, roughly +8% vs. the $1,391.1M reported in the year-ago quarter - Adjusted EPS: ~$2.52, up ~7.7% from $2.34 a year ago
This is the first quarter of the fiscal year for which management set the following full-year guardrails on the May call: - As-reported revenue +7–8%; constant-currency organic +6–7% (FX slightly favorable; tuck-in M&A additive) - Adjusted EPS $11.10–$11.30 (+9–11%) off the $10.17 FY26 base - ~200 bps of price, ~25% effective tax rate, EBIT margin expansion of ~50 bps (at the high end of the range), FCF ~$850M, capex ~$375M
Management was explicit that fiscal 2027 is back-half weighted, and the swing factor is Applied Sterilization Technologies (AST). Two dynamics collide in Q1:
Add in the weather disruption that cost AST an estimated 150–200 bps of growth in the March quarter (some of which may recover), and AST organic growth in Q1 could decelerate sharply into the low-to-mid single digits. Because AST carries the company's richest segment margins (>45% operating margin: $136.7M on $281.2M last Q1), any softness here also pressures the consolidated margin story. Watch the organic number and any commentary on whether med-tech destocking is stabilizing.
1. Healthcare momentum (the growth engine). Healthcare is ~71% of revenue and grew 8% organic in FY26, led by 12% service growth and share gains in consumables. Last Q1 it grew 8% cc organic with 13% service growth — another tough comp. Also note two tuck-in acquisitions (a vertically-integrated MEDglas supplier and a GI-products/channel deal, the latter closing early in Q1) that together add ~$45M to FY27 and roughly 100 bps to Healthcare's reported growth. Watch capital-equipment orders/backlog (total backlog was $490.7M exiting FY26; Healthcare $392.1M) as a read on hospital capital appetite.
2. The tax-rate step-up. A structural headwind to EPS growth this year. The adjusted rate was just 23.5% in Q1 FY26 but guidance assumes ~25% for FY27, driven by geographic mix and withholding taxes incurred when moving cash across borders to fund the dividend, M&A and buybacks. This ~150 bp increase alone is a meaningful drag on EPS conversion — watch the quarterly rate.
3. Tariffs/inflation — now a tailwind vs. the feared headwind. FY26 absorbed ~$46M of incremental tariff cost (~80 bps of margin). For FY27, management modeled flat tariff spend (~$60–65M) and said recent changes actually turned "an okay thing," helping offset volume-driven cost. No tariff refunds are baked into guidance (upside optionality). The bigger swing factor to margin is now freight/fuel and oil-linked raw materials (raws are <20% of COGS). A ~$20M incentive-comp tailwind (normalizing off FY26 overachievement) also supports margins.
4. Life Sciences recovery. Coming off a capital-equipment rebound (+15% in FY26) as pharma capex cycles back. Q1 FY26 was the segment's softest quarter (+4% cc organic), so the comp is easier here. Watch whether the reshoring/big-pharma capex theme and 8%-growing consumables sustain the momentum.
5. Capital returns. The Board authorized a new $1B buyback (2x the prior program), with management committing to a more consistent $200–300M/year pace despite the withholding-tax drag — a notable step-up from the historical "offset dilution" (~$100M) approach. STE also raised its dividend for a 20th straight year ($0.63/qtr). Balance sheet is very strong (gross debt/EBITDA ~1.2x vs. 2.0–2.5x target), leaving ample M&A and buyback capacity.
6. Free cash flow optics. FY27 FCF is guided down to ~$850M from $982.9M in FY26 — not a deterioration in the business, but the lapping of one-time working-capital benefits, plus ~$50M of incentive-comp payouts due in June (this quarter), remaining EtO settlement payments, and higher capex (including the new ~$60M Mentor, Ohio sterility-assurance plant). Q1 FCF was unusually strong last year ($326.5M) on working-capital timing, so a lower Q1 FCF this year would be expected, not alarming.
Fiscal Q1 is a "clear the low bar" quarter by management's own framing — expect decelerating headline organic growth (especially in AST) against tough comps, a higher tax rate compressing EPS conversion, and a lighter FCF quarter. None of that should be a surprise if guidance holds. The more important signals will be qualitative: (1) whether med-tech destocking in AST is bottoming, (2) durability of Healthcare service/consumable share gains and capital orders, and (3) any confirmation that tariffs remain a net tailwind. Given the stock's recent run-up, the risk skews toward a "beat-and-hold-guidance" reaction unless management sounds more confident on the second-half AST reacceleration that underpins the full-year story. Watch for whether they reaffirm, raise, or nudge FX on the $11.10–$11.30 EPS range — early in the year, a reaffirmation is the most likely outcome.
Note: I couldn't confirm the exact release timestamp — STERIS has historically issued the release after market close with the call the next morning; last year's Q1 release hit Aug 6 with the call Aug 7. Confirm timing against the company's IR calendar.